Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pCU shRNA
- Development stage
- Preclinical
- Lead developer
- University of Illinois College of Medicine Peoria
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Gene Addition/Replacement → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing → Gene Therapies
- Administration
- Subcutaneous, Intravenous, Intramuscular, Inhalation, Intranasal, Intradermal, Intrathecal, Intratumoral, Intraperitoneal, Parenteral, Implant
01
Overview
**pCU shRNA** is an experimental plasmid-encoded bicistronic short hairpin RNA construct designed to simultaneously silence expression of urokinase-type plasminogen activator receptor and cathepsin B. It was developed in academic glioma research as a potential antineoplastic gene-silencing approach, including as an adjunct to ionizing radiation. In glioma cell lines, glioma-initiating cells, and mouse xenograft models, pCU-mediated knockdown reduced the target proteins, disrupted pro-invasive and survival signaling, and increased apoptosis and radiation-associated DNA damage. It has not been established as a clinically developed or marketed therapeutic product. ([ncbi.nlm.nih.gov](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367854/))
- Other names
- pCUpUCuPAR and cathepsin B shRNA
02
Targets
Cathepsin B mRNAPlasminogen activator, urokinase receptor mRNA (PLAUR mRNA)
Beyond the preview
Go deeper on pCU shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pCU shRNA.